Author(s): Alessandro M. Vannucchi, Peter te Boekhorst, Claire N. Harrison, Guangsheng He, Marianna Caramella, Dietger Niederwieser, Françoise Boyer-Perrard, Minghui Duan, Nathalie Francillard, Betty Molloy, Monika Wroclawska, Heinz Gisslinger Abstract: PF611 Session topic: 16. Myeloproliferative neoplasms – Clinical Background: Ruxolitinib (RUX, JAK inhibitor) was approved by FDA and EMA for patients (pts) with...
Pro zobrazení tohoto obsahu je třeba být přihlášen.